Breaking News Instant updates and real-time market news.

FB

Facebook

$165.40

2.5 (1.53%)

, ARNA

Arena Pharmaceuticals

$42.80

-1.05 (-2.39%)

09:22
09/25/18
09/25
09:22
09/25/18
09:22

Fly Intel: Pre-market Movers

HIGHER: Arena Pharmaceuticals (ARNA), up 4% after positive topline results from its Phase 2a trial of olorinab, an investigational, full agonist of the cannabinoid receptor 2 in development for the treatment of gastrointestinal pain... Tenaris (TS), up 4% after BofA Merrill Lynch analyst Joao Vicor Lorenzi double upgraded the stock to Buy from Underperform and raised its price target to $40 from $30. Lorenzi expects Tenaris to benefit from a sustained, broad-based recovery in its end markets that should result in a muli-year period of strong earnings momentum... Tilray (TLRY) and Cronos (CRON), up 18% and 4% respectively after New York's Governor yesterday afternoon announced his signing of a bill adding pain management as a condition for medical marijuana. DOWN AFTER EARNINGS: FactSet (FDS), down 5%. LOWER: Opiant Therapeutics (OPNT), down 19% after announcing a common stock offering... TG Therapeutics (TGTX), down 28% after a safety review board said the company's UNITY-CLL trial ORR analysis can not be conducted... CenturyLink (CTL), down 4% after CFO departure... Digital Realty (DLR), down 3% after its 8.5M share secondary offering priced at $113.00... Facebook (FB), down 2% after reports that Instagram co-founders Kevin Systrom and Mike Krieger left the company amid frustrations with Facebook.

FB

Facebook

$165.40

2.5 (1.53%)

ARNA

Arena Pharmaceuticals

$42.80

-1.05 (-2.39%)

TS

Tenaris

$32.99

0.29 (0.89%)

TLRY

Tilray

$99.50

-23.655 (-19.21%)

CRON

Cronos Group

$11.87

-0.64 (-5.12%)

FDS

FactSet

$231.53

-0.05 (-0.02%)

OPNT

Opiant Pharmaceuticals

$21.29

-0.725 (-3.29%)

TGTX

TG Therapeutics

$9.25

0.2 (2.21%)

CTL

CenturyLink

$22.90

-0.04 (-0.17%)

DLR

Digital Realty

$115.95

-5.055 (-4.18%)

  • 25

    Sep

  • 25

    Sep

  • 01

    Oct

  • 02

    Oct

  • 04

    Oct

  • 04

    Oct

  • 22

    Oct

  • 28

    Oct

  • 07

    Nov

  • 25

    Sep

  • 25

    Sep

FB Facebook
$165.40

2.5 (1.53%)

09/18/18
09/18/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. JPMORGAN CUTS ESTIMATES, PRICE TARGET ON FACEBOOK: JPMorgan analyst Doug Anmuth lowered his 2019 and 2020 earnings estimates for Facebook (FB) by 5%-6% on the company's bigger investment increases over the next couple years, which he does not believe are fully captured in consensus estimates. Even with Facebook suggesting it could reach mid-30% operating margins in a few or several years, investments in 2019 could be larger than anticipated in consensus estimates, Anmuth said. The analyst also cut his price target for the shares to $195 from $205. However, he kept an Overweight rating on Facebook. PIVOTAL CUTS DISCOVERY TO SELL: Pivotal Research analyst Brian Wieser downgraded Discovery (DISCA) to Sell with an unchanged price target of $26. Despite "tepid" earnings and "underwhelming" longer-term trends, the stock is up 20% over the past month, Wieser noted. While Discovery's agreements with Hulu and Sling are positive, they do not meaningfully alter the company's fundamentals, the analyst added. His price target implies 19% downside from current share levels. MIZUHO BOOSTS AMD PRICE TARGET: Mizuho analyst Vijay Rakesh raised his price target for AMD (AMD) to $36 from $20 after meeting PC supply chain companies in Asia. AMD's expected server EPYC shipment spike in Q4 will be key, as Intel (INTC) continues to lack a CEO and a competitive technology response to AMD's 12nm Ryzen and 7nm Vega launch, Rakesh said. The analyst, who admits there could be "near-term bumps," kept a Buy rating on shares of AMD. CANACCORD SAYS KAPERNICK AD HAS 'OVERWHELMING' SUPPORT: Canaccord analyst Camilo Lyon conducted a proprietary survey to assess the impact of Nike's (NKE) "Just Do It" ad featuring former NFL quarterback Colin Kapernick. The findings suggest the impact was overall positive and he expects the company to confirm that when it reports Q1 results next week. He believes the ad has had the intended effect of positively skewing the company's brand perception and likely provided a bump in sales. Lyon reiterated his Buy rating and $95 price target on Nike shares. PIPER, WILLIAM BLAIR DEFEND NUTANIX: Nutanix (NTNX) shares dropped 11.5% Monday due to an article from The Information citing a potential competitive hyperconverged infrastructure offering from Google (GOOG, GOOGL), but Piper Jaffray analyst Andrew Nowinski views the selling pressure as "excessive" and reiterates an Overweight rating on Nutanix with a $66 price target. William Blair analyst Jason Ader called the fear of competition from Google "overblown" and reiterated an Outperform rating on Nutanix.
09/25/18
NOMU
09/25/18
NO CHANGE
Target $125
NOMU
Buy
Square price target raised to $125 from $86 at Nomura Instinet
Nomura Instinet analyst Dan Dolev raised his price target for Square (SQ) to $125 from $86 and keeps a Buy rating on the shares. The stock closed yesterday up 75c to $86.04. The analyst's analysis of Square's fundamentals indicates "buoyant" gross payment volume, revenue and marketing efficacy trends. The company's "fully cohesive solutions and rapid rate of innovation" suggest that it is en route to disrupt the global payments ecosystem, Dolev tells investors in a research note titled "Improving Momentum Means $125 Is Within Reach." He believes this is similar to the FANG stocks, or Facebook (FB), Amazon.com (AMZN), Netflix (NFLX) and Google (GOOG, GOOGL), that have "disrupted traditional markets with massive" global total addressable markets. Further, Dolev believes shares of Square are not too expensive when taking into account its "stellar" 45% expected three-year annual revenue growth, which he thinks "makes it screen more attractively than many payment peers and FANG stocks."
09/25/18
BARD
09/25/18
NO CHANGE
Target $195
BARD
Outperform
Facebook survey suggests stabilizing user engagement, says Baird
Baird analyst Colin Sebastian said his latest social media survey suggests stabilizing user engagement on the core Facebook app, following a period of declines. If accurate, the survey suggests concerns over an engagement and monetization-related slowdown may already be reflected in the shares. He also said Q3 estimates embed reasonable expectations for user growth. Sebastian reiterated his Outperform rating and $195 price target on Facebook shares.
09/25/18
JPMS
09/25/18
NO CHANGE
JPMS
Overweight
JPMorgan sees 'meaningful pressure' on Facebook shares from Instagram departures
JPMorgan analyst Doug Anmuth says the "surprising" departure of Instagram co-founders Kevin Systrom and Mike Krieger is concerning and likely to put "meaningful pressure" on shares of Facebook (FB) in the near-term. The analyst believes Instagram has been a strong growth driver for Facebook and has played a critical role in retaining younger users within the company's group of platforms and in competing with Snap (SNAP). While the exact rationale for the co-founders' departure is unclear, various press reports suggest it is related to Facebook management recently exerting more control over Instagram, Anmuth tells investors in a research note. The analyst has an Overweight rating on Facebook. The stock in premarket trading is down 2%, or $3.71, to $161.70.
ARNA Arena Pharmaceuticals
$42.80

-1.05 (-2.39%)

04/19/18
CANT
04/19/18
NO CHANGE
Target $65
CANT
Overweight
Arena's APD371 'another underappreciated asset,' says Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner views Arena Pharmaceuticals' APD371 in Crohn's abdominal pain as "another underappreciated asset." Release of data from clinical testing is expected in Q2, but is unlikely to have a significant impact on the stock given its early nature, Tanner tells investors in a research note. He believes, however, that APD371's underlying pharmacology could positively position the drug candidate favorably versus other cannabinoid receptor modulators. The analyst raised his price target for the shares to $65 from $64 and keeps an Overweight rating on Arena Pharmaceuticals.
09/25/18
CANT
09/25/18
NO CHANGE
Target $65
CANT
Overweight
Arena is 'underpromising and overdelivering,' says Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner says Arena Pharmaceuticals is again "underpromising and overdelivering" after announcing positive data from a Phase 2 trial of olorinab in subjects with abdominal pain associated with Crohn's disease. The analyst says previous conversations with management caused him to adopt a conservative viewpoint as it relates to the likelihood that the trial would yield results that could be interpreted as a clear sign of potential safety and efficacy. He believes last night's data "clearly establish olorinab as a viable drug worthy of advanced development." Tanner reiterates an Overweight rating on Arena Pharmaceuticals with a $65 price target.
03/21/18
SBSH
03/21/18
NO CHANGE
Target $62
SBSH
Buy
Arena Pharmaceuticals price target raised to $62 from $55 at Citi
Citi analyst Joel Beatty raised his price target for Arena Pharmaceuticals to $62 after the company announced positive Phase 2 topline results for etrasimod in ulcerative colitis. The analyst increased his market penetration projections for etrasimod and maintained a 60% probability of success for the drug. He keeps a Buy rating on Arena Pharmaceuticals.
03/20/18
03/20/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Universal Display (OLED) upgraded to Buy from Hold at Gabelli with analyst Hendi Susanto saying he views the negative market response to a Bloomberg report that Apple (AAPL) is designing and producing MicroLED display prototypes as an overreaction and a buying opportunity. 2. Oneok (OKE) upgraded to Buy from Hold at Jefferies with analyst Christopher Sighinolfi saying he is confident in Oneok's ability to hit target returns on $4.2B of its current projects following a recent meeting with management. 3. PPG (PPG) upgraded to Buy from Hold at Deutsche Bank with analyst David Begleiter saying he believes the company's capital deployment and "valuation discount" are attractive. 4. Roku (ROKU) upgraded to Perform from Underperform at Oppenheimer with analyst Jason Helfstein upgraded Roku (ROKU) to Perform citing valuation and the company's opportunity in virtual multichannel video programming distribution. 5. Arena Pharmaceuticals (ARNA) upgraded to Buy from Hold at Needham with analyst Alan Carr citing the company's "impressive results" from its Phase 2 Ulcerative Colitis study, noting that the the safety and tolerability data components are also "encouraging." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
TS Tenaris
$32.99

0.29 (0.89%)

08/31/18
MSCO
08/31/18
NO CHANGE
Target $57
MSCO
Overweight
Tenaris' overdone selloff a tactical buying opportunity, says Morgan Stanley
Morgan Stanley analyst Robert Pulleyn believes the 6% selloff yesterday in Tenaris shares was overdone and he sees a tactical buying opportunity at current levels. Remarking on the impact of the Argentine peso devaluation, Pulleyn noted that Tenaris prices in U.S. dollars and that its input costs are local. While Section 232 is "more complicated and more noisy than expected," the possible exemptions are more steel than OCTG relevant, added Pulleyn, who has an Overweight rating and $57 price target on Tenaris shares.
08/23/18
JEFF
08/23/18
INITIATION
JEFF
Buy
Tenaris initiated with a Buy at Jefferies
Jefferies analyst Alan Spence started Tenaris with a Buy rating saying the company's exposure to the recovering U.S. oil country tubular goods market provides upside potential in 2019.
09/25/18
BOFA
09/25/18
UPGRADE
Target $40
BOFA
Buy
Tenaris upgraded to Buy from Underperform at BofA/Merrill
BofA/Merrill analyst Joao Vicor Lorenzi double upgraded Tenaris to Buy from Underperform and raised its price target to $40 from $30. Lorenzi expects Tenaris to benefit from a sustained, broad based recovery in its end markets that should result in a muli-year period of strong earnings momentum. The analyst also said the recent pullback in shares has created a compelling buying opportunity.
09/10/18
STFL
09/10/18
INITIATION
STFL
Buy
Tenaris initiated with a Buy at Stifel
Stifel analyst Stephen Gengaro initiated Tenaris with a Buy rating and $41 price target. Gengaro believes Tenaris has a solid balance sheet with a net debt-to-capital ratio of under 4% and its track record of returning cash to shareholders, and expects Tenaris to continue to pay out dividends with a distinct possibility of an increase. The analyst is adding Tenaris to the Stifel Select List.
TLRY Tilray
$99.50

-23.655 (-19.21%)

09/06/18
NORL
09/06/18
DOWNGRADE
NORL
Market Perform
Tilray downgraded to Market Perform from Outperform at Northland
09/06/18
09/06/18
DOWNGRADE

Market Perform
Tilray downgraded to Market Perform after 'massive' move up at Northland
As previously reported, Northland analyst Mike Grondahl downgraded Tilray to Market Perform from Outperform. While he continues to see the company playing a "huge role" in the recreational-use cannabis market in Canada and other countries and the medical market in Europe, he also believes the risk/reward is far more balanced following the recent "massive" move in the stock. Though he lowered his rating, Grondahl also sees optionality for Tilray from other new markets, including potentially the U.S. someday, he noted.
09/06/18
09/06/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. ANALYSTS WEIGH IN ON MICRON: Despite recent softness in DRAM spot pricing, the more appropriate metric for Micron Technology (MU) investors to focus on is gross margin, Deutsche Bank analyst Sidney Ho said. On gross margin, the analyst sees Micron benefiting from "solid cost improvement through technology transition" in fiscal 2019. Further, he believes the DRAM market has become more diverse, which should help offset temporary weakness in any given end market. As the company continues to execute on its technology roadmap and delivers solid operating results, Ho expects Micron's stock valuation to re-rate. He kept a Buy rating and $80 price target on Micron. However, Baird analyst Tristan Gerra said Micron is no longer a top large-cap idea, citing its valuation and the likelihood gross margins may be nearing their peak. He also noted DRAM pricing is likely peaking and NAND is in significant oversupply. Gerra maintained an Outperform rating but lowered his price target to $75 from $100 on Micron shares. ARGUS UPGRADES PG&E TO BUY: Argus analyst Jacob Kilstein upgraded PG&E (PCG) to Buy from Hold with a price target of $54, saying the company's recent California legislative victory will reduce its liability for last year's wildfire as its earnings outlook improves. Kilstein further anticipates PG&E to announce a timeline regarding its dividend reinstatement after being forced to suspend its quarterly payout on concerns about its potential wildfire damage responsibility estimated as high as $12B. NORTHLAND DOWNGRADES TILRAY TO MARKET PERFORM: Northland analyst Mike Grondahl downgraded Tilray (TLRY) to Market Perform from Outperform. While he continues to see the company playing a "huge role" in the recreational-use cannabis market in Canada and other countries and the medical market in Europe, he also believes the risk/reward is far more balanced following the recent "massive" move in the stock. JPMORGAN CUTS FRANKLIN RESOURCES TO UNDERWEIGHT: JPMorgan analyst Kenneth Worthington downgraded Franklin Resources (BEN) to Underweight from Neutral and lowered his price target for the shares to $29 from $32. The analyst believes the more recent weakness in emerging markets, and in particular in emerging market debt, will weigh on both Franklin's organic growth and earnings potential. He thinks challenges in emerging markets put additional pressure on "an already challenging growth story characterized by weak fund performance, significant outflows, and declining margins." Worthington continues to have a negative view on the asset management sector.
09/20/18
STFL
09/20/18
NO CHANGE
STFL
Top 22 Canadian cannabis stocks up 127% since Constellation pact, says Stifel
Yesterday's significant outperformance for Canadian cannabis stocks, led by Tilray (TLRY), at one point pushed the total market capitalization for Canadian Licensed Producers above $C80B, before they closed with a combined market cap of C$73B, calculates Stifel analyst Christopher Growe. Since August 15, when Constellation Brands (STZ) announced a pact to invest C$5B into Canopy Growth (CGC), the top 22 Canadian cannabis stocks are up 127% in stock price, noted Growe. A $C73B market cap in relation to what he estimates to be an addressable Canadian market of C$10B is "difficult to fathom," so valuations require global opportunities to be realized, added Growe, who said he questions the pace of development and degree of advantage for these companies. Companies in the cannabis space that can be traded in the U.S. include Aurora Cannabis (ACBFF), CV Sciences (CVSI), Canopy Growth, Cronos Group (CRON) and Tilray.
CRON Cronos Group
$11.87

-0.64 (-5.12%)

08/15/18
ADAM
08/15/18
UPGRADE
ADAM
Hold
Cronos Group upgraded to Hold from Sell at Canaccord
08/15/18
08/15/18
UPGRADE

Hold
Cronos Group upgraded to Hold on 'compelling' new initiatives at Canaccord
As previously reported, Canaccord analyst Matt Bottomley upgraded Cronos Group to Hold from Sell as he believe Cronos has added a number of "compelling" strategic initiatives, such as a supply agreement into Poland's recently legalized medical market; a partnership with MedMen in Canada; the creation of Cronos GrowCo; and the take-or-pay supply agreement with Cura Select of the U.S. Updating for these initiatives lead Bottomley to raise his price target on Cronos shares to C$7.50 from C$6.50.
05/01/18
ADAM
05/01/18
DOWNGRADE
ADAM
Sell
Cronos Group downgraded to Sell from Hold at Canaccord
FDS FactSet
$231.53

-0.05 (-0.02%)

09/17/18
DADA
09/17/18
NO CHANGE
Target $200
DADA
Neutral
FactSet Q4 to meet or 'modestly exceed' consensus, says DA Davidson
DA Davidson analyst Peter Heckmann kept his Neutral rating and $200 price target on FactSet ahead of its Q4 earnings next week, saying the company should "meet or modestly exceed" his estimates. The analyst is positive on the company's recent Merrill Lynch deal - its largest in the last decade - whereby it will become the primary market data provider for Merrill Lynch Wealth Management, estimating the impact from the relationship at $35M-$65M on an annual basis. Heckmann notes that the deal would increase FactSet's Annual Subscription Value by up to 4.5% and expects the company to provide additional details from its impact as part of its initial FY19 outlook.
06/27/18
DADA
06/27/18
NO CHANGE
Target $185
DADA
Neutral
FactSet Q3 mixed on lighter annual subscription value growth, says DA Davidson
DA Davidson analyst Peter Heckmann keeps his Neutral rating and $185 price target on FactSet after its Q3 results, saying the company's organic revenue growth of 5.7% was in line with the first half but organic annual subscription value growth of 5.3% was down from 5.8% in Q2. The analyst also notes that operating margins fell about 110bps over the prior year period to 31%, which was 70bps below his forecast.
06/27/18
WELS
06/27/18
NO CHANGE
Target $190
WELS
Market Perform
FactSet price target raised to $190 from $185 at Wells Fargo
Wells Fargo analyst William Warmington raised his price target for FactSet to $190 from $185 after the company reported Q3 revenue/adjusted EPS inline/slightly ahead of expectations. The analyst reiterates a Market Perform rating on the shares.
06/29/18
OPCO
06/29/18
NO CHANGE
OPCO
Perform
FactSet shares appear fairly valued, says Oppenheimer
Oppenheimer analyst Glenn Greene maintained a Perform rating on FactSet following meetings with the company's management. In a research note to investors, Greene says that the faster growing Analytics, CTS, and Wealth solutions should benefit aggregate annual subscription value, or ASV, growth, but says he is "cognizant" of secular end-market headwinds, and corresponding stagnant aggregate organic ASV growth. Accordingly, he contends that shares appear fairly valued.
OPNT Opiant Pharmaceuticals
$21.29

-0.725 (-3.29%)

06/12/18
CANT
06/12/18
INITIATION
CANT
Cantor expands Specialty Pharmaceuticals coverage with eight names
Cantor Fitzgerald analyst Brandon Folkes last night rolled out coverage on eight names in the Specialty Pharmaceuticals space. He initiated coverage of AcelRx (ACRX), ANI Pharmaceuticals (ANIP), Biohaven Pharmaceutical (BHVN), Collegium Pharmaceutical (COLL), Emergent BioSolutions (EBS), Eagle Pharmaceuticals (EGRX) and Opiant Pharmaceuticals (OPNT) with Overweight ratings. There is still value to be unlocked in these stocks at current valuations with risk/reward profiles that remain to the upside, Folkes told investors in a research note. His top picks are ANI Pharmaceuticals, Emergent BioSolutions and Collegium Pharmaceutical. The analyst rounded out his coverage with a Neutral rating on Momenta (MNTA), saying the recent share rally puts him on the sidelines "for now."
08/29/18
CANT
08/29/18
NO CHANGE
Target $32
CANT
Overweight
Cantor sees value in Opiant after Emergent acquires Adapt Pharma
Cantor Fitzgerald analyst Brandon Folkes believes Emergent BioSolutions' (EBS) acquisition of Adapt Pharma underscores the potential for companies addressing the opioid overdose market. Opiant Pharmaceuticals (OPNT) is developing its own opioid overdose nasal spray, OPNT003, which could be of benefit in cases of synthetic opioid overdoses, such as with fentanyl, Folkes tells investors in a research note. He believes Opiant presents an attractive risk/reward at current share levels, "even if it captures only a portion of the growing market opioid overdose market." Folkes keeps an Overweight rating on the shares with a $32 price target.
06/11/18
CANT
06/11/18
INITIATION
Target $32
CANT
Overweight
Opiant Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
Cantor initiated Opiant Pharmaceuticals with an Overweight and $32 price target.
08/10/18
CANT
08/10/18
NO CHANGE
Target $32
CANT
Overweight
Cantor reiterates Overweight on Opiant ahead of pipeline readouts
Cantor Fitzgerald analyst Brandon Folkes reiterates an Overweight rating on Opiant Pharmaceuticals with a $32 price target following the company's Q2 results. The analyst expect investors to begin to appreciate the market potential of Opiant's pipeline, "which should drive the stock higher." The company is developing treatments focused on multiple addictions as well a new product for opioid overdose, Folkes tells investors in a research note titled "Pipeline Readouts in '18 and '19 Make Us Even More Positive on OPNT Stock."
TGTX TG Therapeutics
$9.25

0.2 (2.21%)

03/08/18
HCWC
03/08/18
NO CHANGE
Target $38
HCWC
Buy
TG Therapeutics price target raised to $38 from $33 at H.C. Wainwright
H.C. Wainwright analyst Edward White raised his price target for TG Therapeutics to $38 following the company's Q4 results. The analyst believes TG has a cash runway "well into" 2019 and he keeps a Buy rating on the shares.
03/08/18
RHCO
03/08/18
NO CHANGE
Target $38
RHCO
Buy
TG Therapeutics price target increased to $38 from $36 at SunTrust
06/04/18
HCWC
06/04/18
NO CHANGE
Target $38
HCWC
Buy
TG Therapeutics ASCO update an incremental positive, says H.C. Wainwright
H.C. Wainwright analyst Edward White said he believes TG Therapeutics' poster presentation at ASCO further supports his view that umbralisib is a differentiated oral PI3K delta inhibitor. White, who notes that the Phase 3 UNITY-CLL trial remains on target for ORR data this summer, keeps a Buy rating and $38 price target on TG Therapeutics shares.
04/24/18
HCWC
04/24/18
NO CHANGE
Target $38
HCWC
Buy
TG Therapeutics updated data 'remains robust,' says H.C. Wainwright
The updated data from TG Therapeutics' (TGTX) Phase 2 study of ublituximab in patients with relapsing forms of multiple sclerosis "remains robust and consistent with previous updates," H.C. Wainwright analyst Edward White tells investors in a research note. The updated data demonstrates continued safety and efficacy with ublituximab, with sustained 99% median B-cell depletion and 100% reduction in T1 Gd-enhancing lesions, the analyst writes. More importantly, White notes, is that an annualized relapse rate of 0.05 was observed at week 24 in 48 patients, which so far is below the ARR observed with Roche's (RHBBY) Ocrevus, the only approved anti-CD20 monoclonal antibody on the market for multiple sclerosis. The analyst views this morning's data positive and reiterates a Buy rating on TG Therapeutics with a $38 price target.
CTL CenturyLink
$22.90

-0.04 (-0.17%)

08/22/18
MOFT
08/22/18
DOWNGRADE
Target $19
MOFT
Sell
CenturyLink downgraded to Sell from Neutral at MoffettNathanson
MoffettNathanson analyst Nicholas Del Deo downgraded CenturyLink to Sell with a $19 price target. The shares closed yesterday up 13c to $23.98.
09/25/18
OPCO
09/25/18
NO CHANGE
Target $24
OPCO
Outperform
CenturyLink CFO departure raises concerns, says Oppenheimer
Oppenheimer analyst Timothy Horan notes CenturyLink (CTL) has announced that CFO Sunit Patel will depart as of September 28th to join T-Mobile (TMUS) to lead the Sprint (S)/T-Mobile merger and integration efforts. The analyst expects weakness in CenturyLink's stock, as investors will likely be concerned with synergy realization after Patel's departure. While Horan says his departure is disappointing, he believes CenturyLink has a deep management bench, and Jeff Storey, CEO, will continue to be the driving force behind restructuring and expense reductions at the company. He reiterates an Outperform rating and $24 price target on the shares.
08/16/18
RBCM
08/16/18
NO CHANGE
Target $27
RBCM
Outperform
CenturyLink price target raised to $27 from $22 at RBC Capital
RBC Capital analyst Jonathan Atkin raised his price target on CenturyLink to $27 and kept his Outperform rating after its "solid" Q2 results and increased FY18 guidance on "stronger-than-expected synergy realization and benefits from portfolio rationalization". The analyst believes that the company's dividend yield is also safe and its operating expense synergy targets are "beatable". Atkin further notes that although CenturyLink's consumer business is "challenged", it only constitutes about 25% of its combined revenue, and its recent Level 3 Communications transaction helps its "pivot to the enterprise business" with "better underlying economics".
07/18/18
07/18/18
DOWNGRADE
Target $17

Market Perform
Adtran downgraded to Market Perform after earnings at Northland
As previously reported, Northland analyst Tim Savageaux downgraded Adtran (ADTN) to Market Perform from Outperform following the company's Q2 report and Q3 revenue guidance that met consensus, stating that he views the shares as fairly valued given that he believes the earnings power needed to support a higher share price is "still a ways off." While Adtran is "slowly but clearly diversifying away" from CenturyLink (CTL), Savageaux has lowered expectations for any snap-back at CenturyLink and sees slower than expected progress at other U.S. Tier 1 telecom companies, he tells investors. The analyst, who reduced his estimates for 2019, cut his price target on Adtran shares to $17 from $20.
DLR Digital Realty
$115.95

-5.055 (-4.18%)

09/20/18
BREN
09/20/18
INITIATION
Target $127
BREN
Hold
Digital Realty initiated with a Hold at Berenberg
Berenberg analyst Nate Crossett started Digital Realty Trust with a Hold rating and $127 price target.
09/25/18
COWN
09/25/18
NO CHANGE
Target $130
COWN
Outperform
Digital Realty growing rapidly as it diversifies, says Cowen
Cowen analyst Colby Synesael noted Digital Realty agreed to buy Brazilian data center provider Ascenty for $2.3B, which he believes will be dilutive to 2019-202 FFO. However, he said the company is growing rapidly while it diversifies its geographic footprint and strengthens its relationship with key HSPs. Synesael reiterated his Outperform rating and $130 price target on Digital Realty shares.
08/08/18
FBCO
08/08/18
NO CHANGE
Target $130
FBCO
Neutral
Digital Realty price target raised to $130 from $101 at Credit Suisse
Credit Suisse analyst Sami Badri raised his price target for Digital Realty to $130 from $101, citing "strong" Q2 results. The analyst reiterates a Neutral rating on the shares.
07/30/18
SBSH
07/30/18
NO CHANGE
Target $131
SBSH
Buy
Digital Realty price target raised to $131 from $119 at Citi
Citi analyst Michael Rollins raised his price target for Digital Realty Trust to $131 citing the company's "strong" Q2 results. He remains a buyer of the stock given "favorable" business momentum, valuation, and the company's ability to leverage its global footprint and campus strategy. The analyst keeps a Buy rating on Digital Realty.

TODAY'S FREE FLY STORIES

BCYC

Bicycle Therapeutics

$0.00

(0.00%)

21:58
05/22/19
05/22
21:58
05/22/19
21:58
Syndicate
Bicycle Therapeutics 4.333M share IPO priced at $14.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

IDYA

IDEAYA Biosciences

$0.00

(0.00%)

21:36
05/22/19
05/22
21:36
05/22/19
21:36
Syndicate
IDEAYA Biosciences 5M share IPO priced at $10.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

MDT

Medtronic

$89.02

1.22 (1.39%)

, HRL

Hormel Foods

$39.48

-0.33 (-0.83%)

20:25
05/22/19
05/22
20:25
05/22/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

MDT

Medtronic

$89.02

1.22 (1.39%)

HRL

Hormel Foods

$39.48

-0.33 (-0.83%)

BBY

Best Buy

$69.26

-0.68 (-0.97%)

BJ

BJ's Wholesale

$26.50

0.94 (3.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 28

    May

  • 29

    May

  • 29

    May

  • 30

    May

  • 11

    Jun

  • 20

    Jun

HFC

HollyFrontier

$42.69

-1.45 (-3.29%)

20:19
05/22/19
05/22
20:19
05/22/19
20:19
Periodicals
Breaking Periodicals news story on HollyFrontier »

HollyFrontier to shut…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PS

Pluralsight

$33.43

-0.58 (-1.71%)

, MSFT

Microsoft

$127.67

0.77 (0.61%)

20:04
05/22/19
05/22
20:04
05/22/19
20:04
Recommendations
Pluralsight, Microsoft analyst commentary at First Analysis »

Meetings with Pluralsight…

PS

Pluralsight

$33.43

-0.58 (-1.71%)

MSFT

Microsoft

$127.67

0.77 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 03

    Jun

  • 03

    Jun

  • 08

    Jun

  • 10

    Jun

  • 11

    Jun

  • 23

    Jun

  • 06

    Aug

GTE

Gran Tierra

$2.09

-0.03 (-1.42%)

19:28
05/22/19
05/22
19:28
05/22/19
19:28
Hot Stocks
Gran Tierra confirms award of 3 Ecuador blocks with 140K acre total area »

Gran Tierra announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGR

Progressive

$80.47

0.44 (0.55%)

19:10
05/22/19
05/22
19:10
05/22/19
19:10
Hot Stocks
Progressive's Sieger sells 7,500 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$157.60

1.83 (1.17%)

19:05
05/22/19
05/22
19:05
05/22/19
19:05
Hot Stocks
Salesforce Ventures launches $125M Europe Trailblazer Fund »

Salesforce announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

  • 06

    Jun

  • 23

    Jun

MRCY

Mercury Systems

$70.96

0.08 (0.11%)

19:05
05/22/19
05/22
19:05
05/22/19
19:05
Syndicate
Mercury Systems 6M share Secondary priced at $69.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 23

    May

RNG

RingCentral

$122.58

0.14 (0.11%)

18:57
05/22/19
05/22
18:57
05/22/19
18:57
Hot Stocks
RingCentral CEO: We have an all in one solution for business communications »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 05

    Jun

  • 13

    Nov

LB

L Brands

$24.29

1.605 (7.08%)

, VIPS

Vipshop

$7.75

0.095 (1.24%)

18:53
05/22/19
05/22
18:53
05/22/19
18:53
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: L…

LB

L Brands

$24.29

1.605 (7.08%)

VIPS

Vipshop

$7.75

0.095 (1.24%)

CPRT

Copart

$64.99

-0.91 (-1.38%)

CTRP

Ctrip

$37.78

-0.09 (-0.24%)

SNPS

Synopsys

$115.10

-0.63 (-0.54%)

AVP

Avon Products

$4.07

0.875 (27.39%)

GILD

Gilead

$67.25

0.73 (1.10%)

IOVA

Iovance Biotherapeutics

$17.71

1.5 (9.25%)

AMGN

Amgen

$173.23

3.61 (2.13%)

NTAP

NetApp

$62.58

-7.43 (-10.61%)

SCVL

Shoe Carnival

$29.65

-2.6 (-8.06%)

HTHT

Huazhu Group

$34.41

-0.47 (-1.35%)

SBLK

Star Bulk Carriers

$8.13

-0.13 (-1.57%)

ONVO

Organovo

$0.78

-0.158 (-16.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 23

    May

  • 31

    May

  • 03

    Jun

  • 06

    Jun

  • 10

    Jun

  • 10

    Jun

  • 13

    Jun

  • 09

    Jul

  • 16

    Jul

  • 17

    Jul

  • 26

    Sep

  • 27

    Sep

HMC

Honda

$25.54

-0.17 (-0.66%)

, TKTDY

Takata

$0.00

(0.00%)

18:53
05/22/19
05/22
18:53
05/22/19
18:53
Hot Stocks
Honda to recall about 19,000 vehicles in the U.S. over faulty inflator kits »

Honda (HMC) will…

HMC

Honda

$25.54

-0.17 (-0.66%)

TKTDY

Takata

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

DSNKY

Daiichi Sankyo

$0.00

(0.00%)

18:39
05/22/19
05/22
18:39
05/22/19
18:39
Periodicals
Breaking Periodicals news story on Daiichi Sankyo »

Daiichi Sankyo in talks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

SPOT

Spotify

$127.10

-5.06 (-3.83%)

18:27
05/22/19
05/22
18:27
05/22/19
18:27
Periodicals
Spotify resets some users' passwords over 'suspicious activity,' TechCrunch says »

Spotify has informed an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDXX

Idexx Laboratories

$250.45

1.24 (0.50%)

18:20
05/22/19
05/22
18:20
05/22/19
18:20
Hot Stocks
Idexx Laboratories CEO: We're at the beginning of our runway for growth »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

OMC

Omnicom

$79.79

-0.3 (-0.37%)

18:15
05/22/19
05/22
18:15
05/22/19
18:15
Hot Stocks
Omnicom CEO sells 60.5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$37.74

0.04 (0.11%)

18:12
05/22/19
05/22
18:12
05/22/19
18:12
Hot Stocks
Boston Scientific initiates trial of WATCHMAN FLX appendage closure platform »

Boston Scientific has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 26

    Jun

  • 13

    Nov

CTRP

Ctrip

$37.63

-0.24 (-0.63%)

18:03
05/22/19
05/22
18:03
05/22/19
18:03
Hot Stocks
Ctrip reports Q1 gross margin 79% vs. 82% a year ago »

Remained consistent with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

CTRP

Ctrip

$37.63

-0.24 (-0.63%)

18:02
05/22/19
05/22
18:02
05/22/19
18:02
Earnings
Breaking Earnings news story on Ctrip »

Ctrip sees Q2 net revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

CTRP

Ctrip

$37.63

-0.24 (-0.63%)

18:01
05/22/19
05/22
18:01
05/22/19
18:01
Earnings
Ctrip reports Q1 adjusted EPS 44c, consensus 24c »

Reports Q1 revenue $1.2B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

CE

Celanese

$100.10

-0.18 (-0.18%)

18:01
05/22/19
05/22
18:01
05/22/19
18:01
Hot Stocks
Celanese announces acetyls product price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRAY

Dentsply Sirona

$54.64

-0.25 (-0.46%)

17:57
05/22/19
05/22
17:57
05/22/19
17:57
Hot Stocks
Dentsply Sirona CFO Alexos to leave company in connection with relocation »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 05

    Jun

SIM

Grupo Simec

$9.23

(0.00%)

17:55
05/22/19
05/22
17:55
05/22/19
17:55
Hot Stocks
Grupo Simec receives noncompliance notification from NYSE »

Grupo Simec announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRT

Copart

$64.78

-1.12 (-1.70%)

17:51
05/22/19
05/22
17:51
05/22/19
17:51
Earnings
Copart reports Q3 adjusted EPS 66c, consensus 62c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 03

    Jun

NVS

Novartis

$83.94

1.555 (1.89%)

17:51
05/22/19
05/22
17:51
05/22/19
17:51
Periodicals
Novartis CEO sees Zolgensma price 'far lower' than $4M-$5M range, Reuters says »

Novartis CEO Vas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 31

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.